GENF.F Stock Overview
Operates as a biotechnology company that focuses on developing biological interventions aimed at tackling the effects of ageing, slowing, and halting the ageing process, and reducing the incidence of age-related diseases with increase in health span in the United Kingdom and Belgium.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Genflow Biosciences plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.042 |
| 52 Week High | UK£0.042 |
| 52 Week Low | UK£0.022 |
| Beta | 2.37 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | 76.25% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -29.50% |
Recent News & Updates
Recent updates
Shareholder Returns
| GENF.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 1.6% | 2.3% |
| 1Y | 76.3% | 23.6% | 35.1% |
Return vs Industry: GENF.F exceeded the US Biotechs industry which returned 21.4% over the past year.
Return vs Market: GENF.F exceeded the US Market which returned 31.5% over the past year.
Price Volatility
| GENF.F volatility | |
|---|---|
| GENF.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.0% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: GENF.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine GENF.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2021 | 5 | Eric Leire | genflowbio.com |
Genflow Biosciences plc, together with its subsidiaries, operates as a biotechnology company that focuses on developing biological interventions aimed at tackling the effects of ageing, slowing, and halting the ageing process, and reducing the incidence of age-related diseases with increase in health span in the United Kingdom and Belgium. Its lead compound is GF-1002, a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. The company is also developing GF-3001, a topical delivery of SIRT6 to the skin; and GF-4001, a non-human pipeline anti-aging for veterinary use.
Genflow Biosciences plc Fundamentals Summary
| GENF.F fundamental statistics | |
|---|---|
| Market cap | US$8.11m |
| Earnings (TTM) | -US$1.97m |
| Revenue (TTM) | US$770.72k |
10.5x
P/S Ratio-4.1x
P/E RatioIs GENF.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GENF.F income statement (TTM) | |
|---|---|
| Revenue | UK£598.04k |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£598.04k |
| Other Expenses | UK£2.13m |
| Earnings | -UK£1.53m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0044 |
| Gross Margin | 100.00% |
| Net Profit Margin | -256.07% |
| Debt/Equity Ratio | 0% |
How did GENF.F perform over the long term?
See historical performance and comparison